What we do
Viriom's main goal is to combat HIV resistance and radically broaden global access to HIV therapy by developing simplified yet effective treatments. Viriom's strategy is based on four main pillars that allow for cost-effective development without compromising innovation:
Viriom Inc. has reduced its business risk by targeting accelerated registrations and launches in developing markets (CIS, Asia, Africa, Latin America), where development to registration costs amount to 15% of the expenses incurred in developed markets (USA, Western Europe, Japan).
This business model allows Viriom to provide affordable treatments to those who are the most vulnerable, since the vast majority of HIV-infected live in developing regions.